Human Data on Pharmacokinetic Interactions of Cannabinoids : A Narrative Review
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Concomitant use of cannabinoids with other drugs may result in pharmacokinetic drug-drug interactions, mainly due to the mechanism involving Phase I and Phase II enzymes and/or efflux transporters. Cannabinoids are not only substrates but also inhibitors or inducers of some of these enzymes and/or transporters. This narrative review aims to provide the available information reported in the literature regarding human data on the pharmacokinetic interactions of cannabinoids with other medications. A search on Pubmed/Medline, Google Scholar, and Cochrane Library was performed. Some studies were identified with Google search. Additional articles of interest were obtained through cross-referencing of published literature. All original research papers discussing interactions between cannabinoids, used for medical or recreational/adult-use purposes, and other medications in humans were included. Thirty-two studies with medicinal or recreational/adult-use cannabis were identified (seventeen case reports/series, thirteen clinical trials, and two retrospective analyses). In three of these studies, a bidirectional pharmacokinetic drug-drug interaction was reported. In the rest of the studies, cannabinoids were the perpetrators, as in most of them, concentrations of cannabinoids were not measured. In light of the widespread use of prescribed and non-prescribed cannabinoids with other medications, pharmacokinetic interactions are likely to occur. Physicians should be aware of these potential interactions and closely monitor drug levels and/or responses. The existing literature regarding pharmacokinetic interactions is limited, and for some drugs, studies have relatively small cohorts or are only case reports. Therefore, there is a need for high-quality pharmacological studies on cannabinoid-drug interactions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Current pharmaceutical design - (2024) vom: 26. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maldonado, Cecilia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cannabidiol |
|---|
| Anmerkungen: |
Date Revised 30.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0113816128288510240113170116 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367791358 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367791358 | ||
| 003 | DE-627 | ||
| 005 | 20240130232300.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0113816128288510240113170116 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1275.xml |
| 035 | |a (DE-627)NLM367791358 | ||
| 035 | |a (NLM)38288797 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maldonado, Cecilia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Human Data on Pharmacokinetic Interactions of Cannabinoids |b A Narrative Review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Concomitant use of cannabinoids with other drugs may result in pharmacokinetic drug-drug interactions, mainly due to the mechanism involving Phase I and Phase II enzymes and/or efflux transporters. Cannabinoids are not only substrates but also inhibitors or inducers of some of these enzymes and/or transporters. This narrative review aims to provide the available information reported in the literature regarding human data on the pharmacokinetic interactions of cannabinoids with other medications. A search on Pubmed/Medline, Google Scholar, and Cochrane Library was performed. Some studies were identified with Google search. Additional articles of interest were obtained through cross-referencing of published literature. All original research papers discussing interactions between cannabinoids, used for medical or recreational/adult-use purposes, and other medications in humans were included. Thirty-two studies with medicinal or recreational/adult-use cannabis were identified (seventeen case reports/series, thirteen clinical trials, and two retrospective analyses). In three of these studies, a bidirectional pharmacokinetic drug-drug interaction was reported. In the rest of the studies, cannabinoids were the perpetrators, as in most of them, concentrations of cannabinoids were not measured. In light of the widespread use of prescribed and non-prescribed cannabinoids with other medications, pharmacokinetic interactions are likely to occur. Physicians should be aware of these potential interactions and closely monitor drug levels and/or responses. The existing literature regarding pharmacokinetic interactions is limited, and for some drugs, studies have relatively small cohorts or are only case reports. Therefore, there is a need for high-quality pharmacological studies on cannabinoid-drug interactions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cannabidiol | |
| 650 | 4 | |a delta (9)-tetrahydrocannabinol | |
| 650 | 4 | |a drug interactions | |
| 650 | 4 | |a medicinal cannabis | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a review. | |
| 700 | 1 | |a Peyraube, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Fagiolino, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Oricchio, Florencia |e verfasserin |4 aut | |
| 700 | 1 | |a Cuñetti, Leticia |e verfasserin |4 aut | |
| 700 | 1 | |a Vázquez, Marta |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical design |d 1998 |g (2024) vom: 26. Jan. |w (DE-627)NLM095430172 |x 1873-4286 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:26 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0113816128288510240113170116 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 26 |c 01 | ||